PL410078A1 - System nośników kwasów nukleinowych, sposób przygotowania systemu oraz ich zastosowanie - Google Patents
System nośników kwasów nukleinowych, sposób przygotowania systemu oraz ich zastosowanieInfo
- Publication number
- PL410078A1 PL410078A1 PL410078A PL41007814A PL410078A1 PL 410078 A1 PL410078 A1 PL 410078A1 PL 410078 A PL410078 A PL 410078A PL 41007814 A PL41007814 A PL 41007814A PL 410078 A1 PL410078 A1 PL 410078A1
- Authority
- PL
- Poland
- Prior art keywords
- glycerol
- phosphatidylethanolamine
- phosphatidylcholine
- preparation
- dioleyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 239000000969 carrier Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 abstract 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 abstract 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 abstract 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 abstract 1
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 abstract 1
- KYLYEZUDQSQIRP-UHFFFAOYSA-N D,L-(alpha-Glyceryl)-2-(dimethylammonium)-aethylphosphat Natural products CN(C)CCOP(O)(=O)OCC(O)CO KYLYEZUDQSQIRP-UHFFFAOYSA-N 0.000 abstract 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 abstract 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229920001731 Polyprenol Polymers 0.000 abstract 1
- 229930186185 Polyprenol Natural products 0.000 abstract 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 abstract 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- -1 phosphatidyl monomethylethanolamine Chemical compound 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 150000003096 polyprenols Chemical class 0.000 abstract 1
- 229920001550 polyprenyl Polymers 0.000 abstract 1
- 125000001185 polyprenyl group Polymers 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem wynalazku jest system zawierający jako nośniki kwasów nukleinowych kationowe pochodne poliprenoli, o różnej długości łańcucha poliprenylowego o wzorze 1 oraz lipidy pomocnicze wybrane z grupy obejmującej DOPE (1,2-dioleilo-sn-glicero-3- fosfatydyloetanoloamina), cholesterol, DC-cholesterol [chlorowodorek {3ß-[N-(N',N'-dimetyloaminoetan)-karbamoilo]cholesterolu}], DOPC: (1,2-dioleilo-sn-glicero-3-fosfatydylocholina), DMPC (1,2-dimirystylo-sn-glicero-3-fosfatydylocholina), DMPE (1,2-dimirystylo-sn-glicero-3-fosfatydyloetanoloamina), DLPC (1,2-dilaurylo-sn-glicero-3-fosfatydylocholina), DPPC (1,2-dipalmitylo-sn-glicero-3-fosfatydylocholina), fosfatydylocholina, fosfatydyloetanoloamina, DPPE (1,2-dipalmitylo-sn-glicero-3-fosfatydyloetanoloamina), DLPE (2-dilaurylo-sn-glicero-3-fosfatydyloetanoloamina), DOPS (1,2-dioleilo-sn-glicero-3-fosfatydyloseryna), POPC (1-palmitylo-2-oleilo-sn-glicero-3-fosfatydylocholina), PDME (fosfatydylo-N,N-dimetyloetanoloamina), DSPE (1,2-distearylo-sn-glicero-3-fosfatydyloetanoloamina), DSPC (1,2-distearylo-SA7-glicero-3- fosfatydylocholina), POPE (1-palmitylo-2-oleilo-sn-glicero-3-fosfatydyletanoloamina), PMME (fosfatydylo-monometyloetanoloamina), a także, ewentualnie, może zawierać substancje modyfikujące powierzchnię lipopleksów. Ujawniono także sposób przygotowania i zastosowanie systemu określonego powyżej do przygotowania preparatów do wprowadzania kwasów nukleinowych do komórek eukariotycznych.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLP-409298 | 2014-08-28 | ||
| PL40929814 | 2014-08-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL410078A1 true PL410078A1 (pl) | 2016-02-29 |
| PL230096B1 PL230096B1 (pl) | 2018-09-28 |
Family
ID=55361206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL410063A PL231158B1 (pl) | 2014-08-28 | 2014-11-04 | Szczepionka, kompozycja farmaceutyczna, nośnik kwasów nukleinowych oraz innych substancji aktywnych biologicznie, zastosowanie kompozycji do wytwarzania szczepionki oraz zastosowanie kationowych pochodnych poliprenoli PTAI do wytwarzania substancji immunomodulujących |
| PL410078A PL230096B1 (pl) | 2014-08-28 | 2014-11-06 | System nośników kwasów nukleinowych, sposób przygotowania systemu oraz ich zastosowanie |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL410063A PL231158B1 (pl) | 2014-08-28 | 2014-11-04 | Szczepionka, kompozycja farmaceutyczna, nośnik kwasów nukleinowych oraz innych substancji aktywnych biologicznie, zastosowanie kompozycji do wytwarzania szczepionki oraz zastosowanie kationowych pochodnych poliprenoli PTAI do wytwarzania substancji immunomodulujących |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3185893B1 (pl) |
| PL (2) | PL231158B1 (pl) |
| WO (1) | WO2016032348A1 (pl) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10229872A1 (de) * | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| PL211824B1 (pl) | 2007-05-17 | 2012-06-29 | Inst Biochemii I Biofizyki Pan | Trimetyloaminowe pochodne poli-cis i poli-trans liniowych oligomerów izoprenowych, sposób ich wytwarzania oraz ich zastosowanie |
-
2014
- 2014-11-04 PL PL410063A patent/PL231158B1/pl unknown
- 2014-11-06 PL PL410078A patent/PL230096B1/pl unknown
-
2015
- 2015-06-12 EP EP15739689.6A patent/EP3185893B1/en active Active
- 2015-06-12 WO PCT/PL2015/000093 patent/WO2016032348A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL230096B1 (pl) | 2018-09-28 |
| EP3185893B1 (en) | 2023-07-05 |
| WO2016032348A1 (en) | 2016-03-03 |
| EP3185893A1 (en) | 2017-07-05 |
| PL410063A1 (pl) | 2016-02-29 |
| PL231158B1 (pl) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| WO2015184256A3 (en) | Biodegradable lipids for delivery of nucleic acids | |
| WO2017180917A3 (en) | Lipid compositions and their uses for intratumoral polynucleotide delivery | |
| EP4450487A3 (en) | Lipids for lipid nanoparticle delivery of active agents | |
| MX2024001218A (es) | Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia. | |
| EP4501322A3 (en) | Lipids for use in lipid nanoparticle formulations | |
| EP3964200A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| MX2021003421A (es) | Formulaciones de nanoparticulas lipidicas que comprenden compuestos peptidicos cationicos lipidados para el suministro de acidos nucleicos. | |
| MX2019011004A (es) | Compuestos y composiciones para la administracion intracelular de agentes terapeuticos. | |
| RU2017113970A (ru) | Стабильные составы липидов и липосом | |
| EP4036079A3 (en) | Compounds and compositions for intracellular delivery of agents | |
| JP2020514366A5 (pl) | ||
| EP4286012A3 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| MX2018001491A (es) | Metodos para la preparacion de acidos biliares y derivados de los mismos. | |
| AR086409A1 (es) | Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino | |
| AU2009339445A1 (en) | Methods of reducing the proliferation and viability of microbial agents | |
| MX2024005714A (es) | Lípidos catiónicos ionizables para la administración de arn. | |
| MX385488B (es) | Lipido cationico. | |
| AR108036A1 (es) | Formulaciones liposomales y métodos de uso de las mismas en agricultura | |
| MX2020005247A (es) | Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico. | |
| MA43066A (fr) | Procédés de préparation d'acides biliaires et de leurs dérivés | |
| RU2019115688A (ru) | Липосомальный препарат для применения для лечения злокачественного новообразования | |
| IL313681A (en) | Inhibiting ataxia telangiectasia and rad3-related protein (atr) | |
| MX385343B (es) | Una composición multilamelar acuosa para suministrar sustancia hidrofóbicas. | |
| WO2023104114A3 (en) | Rna formulations and lipids |